- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
The FDA approved the influenza vaccine for self-administration, while the CDC concurrently classified the previous influenza season as high-severity.
1 report, 1 independent
Updated Aug 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA approved the influenza vaccine for self-administration, while the CDC concurrently classified the previous influenza season as high-severity.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
-
Centers for Disease Control and Prevention
government organization in Kampala, Uganda
- FDA
-
AstraZeneca
British-Swedish pharmaceutical company
Related events
Coverage
Newest first; wire copies grouped- Business WireFLUMIST (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery AstraZeneca launches the first FDA-approved influenza vaccine available for s